ATE233101T1 - Polynukleotide vakzine gegen den papilloma virus - Google Patents

Polynukleotide vakzine gegen den papilloma virus

Info

Publication number
ATE233101T1
ATE233101T1 AT95922160T AT95922160T ATE233101T1 AT E233101 T1 ATE233101 T1 AT E233101T1 AT 95922160 T AT95922160 T AT 95922160T AT 95922160 T AT95922160 T AT 95922160T AT E233101 T1 ATE233101 T1 AT E233101T1
Authority
AT
Austria
Prior art keywords
pct
papilloma virus
vaccine against
polynucleotide vaccine
sec
Prior art date
Application number
AT95922160T
Other languages
English (en)
Inventor
John J Donnelly
Margaret A Liu
Douglas Martinez
Donna L Montgomery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE233101T1 publication Critical patent/ATE233101T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT95922160T 1994-06-30 1995-06-01 Polynukleotide vakzine gegen den papilloma virus ATE233101T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30
PCT/US1995/006915 WO1996000583A1 (en) 1994-06-30 1995-06-01 Polynucleotide vaccine for papillomavirus

Publications (1)

Publication Number Publication Date
ATE233101T1 true ATE233101T1 (de) 2003-03-15

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922160T ATE233101T1 (de) 1994-06-30 1995-06-01 Polynukleotide vakzine gegen den papilloma virus

Country Status (20)

Country Link
US (1) US5866553A (de)
EP (1) EP0768893B1 (de)
JP (1) JPH10501987A (de)
CN (1) CN1156966A (de)
AT (1) ATE233101T1 (de)
AU (1) AU701973B2 (de)
CA (1) CA2193365C (de)
CZ (1) CZ375296A3 (de)
DE (1) DE69529748T2 (de)
ES (1) ES2191052T3 (de)
FI (1) FI965224A0 (de)
HU (1) HU220747B1 (de)
IL (1) IL113817A (de)
MX (1) MX9700229A (de)
NO (1) NO965590L (de)
NZ (1) NZ288045A (de)
PL (1) PL180639B1 (de)
SK (1) SK164196A3 (de)
WO (1) WO1996000583A1 (de)
ZA (1) ZA954641B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
AU722326B2 (en) * 1997-02-14 2000-07-27 Merck & Co., Inc. Polynucleotide vaccine formulations
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU3489499A (en) * 1998-04-14 1999-11-01 Merck & Co., Inc. Needleless administration of polynucleotide formulations
NZ510488A (en) * 1998-09-04 2003-07-25 Aventis Pasteur Immunotherapy for HPV DNA-positive cervical cancers with DNA constructs for the administration of HPV antigens to provide an immune response in a host
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
CA2365416C (en) * 1999-03-26 2011-06-14 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
EP1212358B1 (de) * 1999-08-25 2004-12-15 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
EP1372708B1 (de) * 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Impstoffe zur transkutanen immunisierung gegen reisediarrhö
BR0210586A (pt) * 2001-06-22 2005-07-12 Wistar Inst Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
CA2509973C (en) * 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
KR20070002014A (ko) * 2004-02-13 2007-01-04 노드 파마수티칼스, 인코포레이티드 치료용 인산칼슘 입자, 그 제조 방법 및 그 이용 방법
US20090041812A1 (en) * 2004-11-01 2009-02-12 Bell Steve J D Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
CN101193653B (zh) * 2005-02-01 2013-03-27 美国政府健康及人类服务部 用于诱导广泛交叉中和抗体的***瘤病毒l2 n末端肽
CN101293918B (zh) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人***瘤病毒16型l1蛋白
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
CN101343315B (zh) * 2007-05-29 2012-06-13 厦门大学 截短的人***瘤病毒6型l1蛋白
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
WO1986005816A1 (en) * 1985-04-04 1986-10-09 Georgetown University Type-specific papillomavirus dna sequences and peptides
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
ATE277193T1 (de) * 1989-03-21 2004-10-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
CA2113712C (en) * 1991-07-19 2007-06-12 Ian Frazer Papilloma virus vaccine
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
ES2201055T3 (es) * 1992-08-07 2004-03-16 Wyeth Vacunas de adenovirus recombinante.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
NZ288045A (en) 1998-08-26
DE69529748T2 (de) 2003-10-16
NO965590L (no) 1997-02-28
HUT76446A (en) 1997-09-29
JPH10501987A (ja) 1998-02-24
EP0768893B1 (de) 2003-02-26
CA2193365A1 (en) 1996-01-11
ES2191052T3 (es) 2003-09-01
CN1156966A (zh) 1997-08-13
IL113817A0 (en) 1995-08-31
PL317874A1 (en) 1997-04-28
AU701973B2 (en) 1999-02-11
WO1996000583A1 (en) 1996-01-11
HU220747B1 (hu) 2002-05-28
IL113817A (en) 2001-03-19
HU9603562D0 (en) 1997-02-28
ZA954641B (en) 1996-01-26
AU2694595A (en) 1996-01-25
US5866553A (en) 1999-02-02
DE69529748D1 (de) 2003-04-03
SK164196A3 (en) 1997-08-06
FI965224A (fi) 1996-12-27
CZ375296A3 (en) 1997-08-13
NO965590D0 (no) 1996-12-27
FI965224A0 (fi) 1996-12-27
PL180639B1 (pl) 2001-03-30
EP0768893A1 (de) 1997-04-23
CA2193365C (en) 2007-04-03
MX9700229A (es) 1997-04-30

Similar Documents

Publication Publication Date Title
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
TR200001835T2 (tr) Aşı.
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
ATE267211T1 (de) Impfstoff gegen hpv
CA2201587A1 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
YU12894A (sh) Farmaceutski preparat na bazi nukleinske kiseline
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
FI960977A0 (fi) Bakteeriperäiset eksportoidut proteiinit ja niihin perustuvat asellulaariset rokotteet
ES2178657T3 (es) Derivados lipopeptidos, procedimiento para su preparacion y su empleo.
PL307049A1 (en) Vaccines against pseudohydrophobia and other animal diseases caused by pseudohydrophobia viruses
FI972170A0 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
DE10399019I1 (de) Gefluegelkrankheit verursachende neue Bakterie unddaraus stammender Impfstoff
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları
AU6722498A (en) Disubstituted biphenyloxazolines
SE9401596D0 (sv) New compounds
TR200402685T4 (tr) Merkezi sinir sistemi üzerine etki eden siklobüta-indol karboksamid türevleri, bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler.
EA200200491A1 (ru) Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцины и их применение в качестве лекарственных средств
NO982151L (no) Hemoregulatoriske forbindelser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties